Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study of Nanobodies targeting a G-protein-coupled receptor (GPCR) in the treatment of inflammation

Next Previous
Trial Profile

A phase I study of Nanobodies targeting a G-protein-coupled receptor (GPCR) in the treatment of inflammation

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 19 May 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Single-domain antibodies (Primary)
  • Indications Inflammation
  • Focus Adverse reactions

Most Recent Events

  • 12 May 2016 According to an Ablynx media release, Novartis received clearance by the FDA to start this phase I study.
  • 09 May 2016 New trial record
  • 29 Apr 2016 According to an Ablynx media release, the company has received clearance of the Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for this phase I study which is expected to initiate in the second quarter of 2016.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top